{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:26:30Z","timestamp":1784953590769,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"42-43","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.vaccine.2006.06.035","type":"journal-article","created":{"date-parts":[[2006,7,7]],"date-time":"2006-07-07T10:21:22Z","timestamp":1152267682000},"page":"6493-6502","source":"Crossref","is-referenced-by-count":22,"title":["Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques"],"prefix":"10.1016","volume":"24","author":[{"given":"V. Ann","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon M.","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent E.","family":"Kester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Delchambre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Gar\u00e7on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"D. Gray","family":"Heppner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2006.06.035_bib1","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1046\/j.1365-3156.2001.00752.x","article-title":"Controlling malaria: challenges and solutions","volume":"6","author":"Olliaro","year":"2001","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.vaccine.2006.06.035_bib2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1473-3099(02)00372-9","article-title":"Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development","volume":"2","author":"Guerin","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2006.06.035_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0065-308X(02)52013-3","article-title":"The consequences of reducing transmission of Plasmodium falciparum in Africa","volume":"52","author":"Snow","year":"2002","journal-title":"Adv Parasitol"},{"key":"10.1016\/j.vaccine.2006.06.035_bib4","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(03)13366-1","article-title":"Forecasting, warning, and detection of malaria epidemics: a case study","volume":"361","author":"Hay","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2006.06.035_bib5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1471-4922(03)00054-0","article-title":"The puzzling links between malaria transmission and drug resistance","volume":"19","author":"Ariey","year":"2003","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2006.06.035_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000058848","article-title":"Pre-erythrocytic malaria vaccines to prevent Plasmodium falciparum malaria","volume":"80","author":"Ballou","year":"2002","journal-title":"Chem Immunol"},{"key":"10.1016\/j.vaccine.2006.06.035_bib7","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.vaccine.2005.01.142","article-title":"Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research","volume":"23","author":"Heppner","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.06.035_bib8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1517\/14728214.10.3.489","article-title":"Malaria vaccines in development","volume":"10","author":"Ballou","year":"2005","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.vaccine.2006.06.035_bib9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/14760584.2.2.231","article-title":"Development of RTS,S\/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant","volume":"2","author":"Garcon","year":"2003","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2006.06.035_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM199701093360202","article-title":"A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group","volume":"336","author":"Stoute","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2006.06.035_bib11","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1086\/318534","article-title":"Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria","volume":"183","author":"Kester","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.06.035_bib12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4269\/ajtmh.2004.71.239","article-title":"Update on the clinical development of candidate malaria vaccines","volume":"71","author":"Ballou","year":"2004","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.06.035_bib13","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4269\/ajtmh.2006.75.166","article-title":"Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S\/AS02A in adults in a hyperendemic region of western Kenya","volume":"75","author":"Stoute","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.06.035_bib14","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1086\/315074","article-title":"Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S\/SBAS2, a recombinant Plasmodium falciparum malaria vaccine","volume":"180","author":"Lalvani","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.06.035_bib15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2249.2004.02371.x","article-title":"Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S\/AS02, in semi-immune adults in The Gambia","volume":"135","author":"Pinder","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2006.06.035_bib16","doi-asserted-by":"crossref","first-page":"6961","DOI":"10.4049\/jimmunol.171.12.6961","article-title":"Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4(+) and CD8(+) T cells producing IFN-gamma","volume":"171","author":"Sun","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2006.06.035_bib17","doi-asserted-by":"crossref","first-page":"865","DOI":"10.4269\/ajtmh.1999.61.865","article-title":"A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S\/SBAS2 in semi-immune adults in The Gambia","volume":"61","author":"Doherty","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.06.035_bib18","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1086\/515657","article-title":"Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine","volume":"178","author":"Stoute","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.06.035_bib19","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(01)06957-4","article-title":"Efficacy of RTS,S\/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial","volume":"358","author":"Bojang","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2006.06.035_bib20","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(05)67669-6","article-title":"Duration of protection with RTS,S\/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial","volume":"366","author":"Alonso","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2006.06.035_bib21","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1016\/j.vaccine.2006.06.033","article-title":"Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S\/AS02A","volume":"24","author":"Stewart","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.06.035_bib22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4269\/ajtmh.2004.70.499","article-title":"Safety and immunogenicity of RTS,S+TRAP malaria vaccine, formulated in the AS02A adjuvant system, in infant rhesus monkeys","volume":"70","author":"Walsh","year":"2004","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.06.035_bib23","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1016\/j.vaccine.2004.07.023","article-title":"Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum","volume":"22","author":"Pichyangkul","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.06.035_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0090-1229(95)90141-8","article-title":"Cutaneous delayed-type hypersensitivity responsiveness in patients during and after Plasmodium falciparum and Plasmodium vivax infections","volume":"77","author":"Walsh","year":"1995","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2006.06.035_bib25","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1086\/516517","article-title":"Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons","volume":"176","author":"Sitz","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.06.035_bib26","first-page":"3","article-title":"Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major","volume":"72","author":"Yang","year":"1991","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2006.06.035_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00389929","article-title":"Delayed dermal hypersensitivity in rhesus monkeys (Macaca mulatta) immunized against Plasmodium knowlesi","volume":"50","author":"Cabrera","year":"1976","journal-title":"Z Parasitenkd"},{"key":"10.1016\/j.vaccine.2006.06.035_bib28","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0264-410X(02)00037-3","article-title":"Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites","volume":"20","author":"Kublin","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.06.035_bib29","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1016\/j.vaccine.2005.03.042","article-title":"An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model","volume":"23","author":"Putnak","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.06.035_bib30","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4049\/jimmunol.164.3.1617","article-title":"Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo","volume":"164","author":"Hartmann","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2006.06.035_bib31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0378-4347(01)00340-1","article-title":"Two-step chromatographic purification of recombinant Plasmodium falciparum circumsporozoite protein from Escherichia coli","volume":"762","author":"Kolodny","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.vaccine.2006.06.035_bib32","first-page":"163","article-title":"Kinetic expression of endothelial adhesion molecules and relationship to leukocyte recruitment in two cutaneous models of inflammation","volume":"70","author":"Silber","year":"1994","journal-title":"Lab Invest"},{"key":"10.1016\/j.vaccine.2006.06.035_bib33","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1172\/JCI117134","article-title":"Recruitment of lymphocytes during cutaneous delayed hypersensitivity in nonhuman primates is dependent on E-selectin and vascular cell adhesion molecule 1","volume":"93","author":"Silber","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2006.06.035_bib34","first-page":"313","article-title":"Characterization of nonhuman primate epidermal and dermal dendritic cells with monoclonal antibodies","volume":"56","author":"Ringler","year":"1987","journal-title":"Lab Invest"},{"key":"10.1016\/j.vaccine.2006.06.035_bib35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S1472-9792(02)00059-8","article-title":"Non-human primates: a model for tuberculosis research","volume":"83","author":"Flynn","year":"2003","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.vaccine.2006.06.035_bib36","unstructured":"http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00075049. Accessed 14 May 2006."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06007390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06007390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T18:18:06Z","timestamp":1555697886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06007390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":36,"journal-issue":{"issue":"42-43","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0264410X06007390"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.06.035","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}